Merck & Co.'s Gardasil approved in Canada

Health Canada approved Merck & Co.'s cervical cancer vaccine Gardasil on Tuesday. The vaccine will be available in the country at the end of next month.

The vaccine, which prevents two strains of human papillomavirus (HPV) believed to cause about 70 percent of cervical cancer cases, is indicated in Canada for females between 9 and 26 years old, as a preventative agent to cervical, vulvar and vaginal cancers, precancerous lesions and warts caused by HPV, news sources report. Gardasil also protects women against two other strains of HPV that are responsible for 90 per cent of genital wart cases in clinical trials.

Gardasil garnered FDA approval last month.

To read more Top Story articles, click here.